PMID- 19556381
OWN - NLM
STAT- MEDLINE
DCOM- 20090923
LR  - 20220408
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Print)
IS  - 1555-9041 (Linking)
VI  - 4
IP  - 7
DP  - 2009 Jul
TI  - Contrast-induced nephropathy and long-term adverse events: cause and effect?
PG  - 1162-9
LID - 10.2215/CJN.00550109 [doi]
AB  - BACKGROUND AND OBJECTIVES: The relationship of contrast-induced nephropathy (CIN) 
      to long-term adverse events (AEs) is controversial. Although an association with 
      AEs has been previously reported, it is unclear whether CIN is causally related 
      to these AEs. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We obtained 
      long-term (> or =1 yr) follow-up on 294 patients who participated in a 
      randomized, double-blind comparison of two prevention strategies for CIN 
      (iopamidol versus iodixanol). A difference in the incidence of AEs between 
      patients who had developed CIN and those who had not was performed using a chi(2) 
      test and Poisson regression analysis. A similar statistical approach was used for 
      the differences in AEs between those who received iopamidol or iodixanol. 
      Multiple definitions of CIN were used to strengthen and validate the results and 
      conclusions. RESULTS: The rate of long-term AEs was higher in individuals with 
      CIN (all definitions of CIN). After adjustment for baseline comorbidities and 
      risk factors, the adjusted incidence rate ratio for AEs was twice as high in 
      those with CIN. Randomization to iopamidol reduced both the incidence of CIN and 
      AEs. CONCLUSIONS: The parallel decrease in the incidence of CIN and AEs in one 
      arm of this randomized trial supports a causal role for CIN.
FAU - Solomon, Richard J
AU  - Solomon RJ
AD  - Department of Renal Services, Fletcher Allen Health Care, Burlington, VT 05401, 
      USA. richard.solomon@vtmednet.org
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Natarajan, Madhu K
AU  - Natarajan MK
FAU - Doucet, Serge
AU  - Doucet S
FAU - Katholi, Richard E
AU  - Katholi RE
FAU - Staniloae, Cezar S
AU  - Staniloae CS
FAU - Sharma, Samin K
AU  - Sharma SK
FAU - Labinaz, Marino
AU  - Labinaz M
FAU - Gelormini, Joseph L
AU  - Gelormini JL
FAU - Barrett, Brendan J
AU  - Barrett BJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00479024
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090625
PL  - United States
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
RN  - 0 (CST3 protein, human)
RN  - 0 (Contrast Media)
RN  - 0 (Cystatin C)
RN  - 0 (Triiodobenzoic Acids)
RN  - AYI8EX34EU (Creatinine)
RN  - HW8W27HTXX (iodixanol)
RN  - JR13W81H44 (Iopamidol)
SB  - IM
CIN - Clin J Am Soc Nephrol. 2009 Jul;4(7):1151-3. PMID: 19541810
MH  - Acute Kidney Injury/*chemically induced/epidemiology/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Comorbidity
MH  - Contrast Media/*adverse effects
MH  - Creatinine/blood
MH  - Cystatin C/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Diseases/*diagnostic imaging
MH  - Humans
MH  - Incidence
MH  - Iopamidol/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Radiography
MH  - Risk Factors
MH  - Time Factors
MH  - Triiodobenzoic Acids/*adverse effects
MH  - Young Adult
PMC - PMC2709519
EDAT- 2009/06/27 09:00
MHDA- 2009/09/24 06:00
PMCR- 2010/07/01
CRDT- 2009/06/27 09:00
PHST- 2009/06/27 09:00 [entrez]
PHST- 2009/06/27 09:00 [pubmed]
PHST- 2009/09/24 06:00 [medline]
PHST- 2010/07/01 00:00 [pmc-release]
AID - CJN.00550109 [pii]
AID - 0109 [pii]
AID - 10.2215/CJN.00550109 [doi]
PST - ppublish
SO  - Clin J Am Soc Nephrol. 2009 Jul;4(7):1162-9. doi: 10.2215/CJN.00550109. Epub 2009 
      Jun 25.